Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma

Table 5 Comparative analysis of tumor biomarker responses between the two groups, mean ± SD

	Experimental group (n = 45)	Control group (n = 44)	F value	P value
CEA, ng/mL			164.563	< 0.001
Before treatment	34.57 ± 2.35	34.62 ± 2.32	0.017	0.897
3 months after treatment	18.14 ± 1.27	22.59 ± 1.92
AFP, ng/mL			1019.687	< 0.001
Before treatment	434.52 ± 12.05	433.59 ± 12.16	0.831	0.364
3 months after treatment	251.25 ± 16.58	362.91 ± 16.38
PIVKA-II, mAU/mL			6.165	0.015
Before treatment	723.14 ± 201.20	724.34 ± 202.54	0.226	0.636
3 months after treatment	559.25 ± 157.45	643.82 ± 162.25
CA199, U/mL			257.831	< 0.001
Before treatment	254.81 ± 10.56	255.85 ± 10.06	2.111	0.150
3 months after treatment	179.58 ± 5.62	201.49 ± 7.28

CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein; PIVKA-II: Abnormal prothrombin; CA199: Carbohydrate antigen 199.